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OI-A-3
MENOPAUSAL STATUS AND ESTROGEN RECEPTOR GE-
NOTYPES INFLUENCED THE SEVERITY OF HOT FLASHES
AFTER TAMOXIFEN TREATMENT. Y. Jin, MD, T. Skaar, PhD,
A. Storniolo, MD, Z. Desta, PhD, A. Nguyen, L. Li, PhD, D. Hayes,
MD, D. A. Flockhart, MD, PhD, V. Stearns, MD, Indiana Univer-
sity, University of Michigan, Indianapolis, IN.
BACKGROUND/AIMS: Hot flashes are the most common side
effect of tamoxifen treatment. We conducted a prospective observa-
tional trial to evaluate factors that influenced hot flash severity after
tamoxifen treatment.
METHODS: Hot flashes frequency and severity were recorded in
7-day hot flashes diaries before, and 1, 4, 8, 12 months after tamox-
ifen treatment in 122 subjects. Hot flashes composit scores were
calculated. Demographic information was collected at baseline, and
estrogen receptor (ESR1 & 2) genotyping was also performed.
RESULTS: Pre-menopausal women showed the biggest increase
in hot flashes severity, from 5.210.5 at baseline to 28.551.6 at 4
month (P0.0001), whereas there was no significant change in peri-
or postmenopausal women. Twenty-two of the 122 women did not
develop hot flashes. G allele carriers of the ESR2-02 SNP were 4.2
times more likely to develop hot flashes than homozygotes with AA
genotype (P0.008).
CONCLUSION: Pre-menopausal women were most likely to
develop hot flashes after tamoxifen treatment. ESR2-02 genotype
may also influence the risk of developing hot flashes after tamoxifen
treatment.
OI-A-4
GENOME-WIDE APPROACH TO FINDING DETERMI-
NANTS OF SUSCEPTIBILITY TO CHEMOTHERAPEUTIC
AGENTS. S. Shukla, MPH, J. Badner, MD, PhD, C. Cheng, PhD,
W. Bleibel, BA, M. E. Dolan, PhD, University of Chicago, St.
Jude’s Children’s Research Hopsital, Chicago, IL.
BACKGROUND: Our aim was to identify candidate genes and
genetic variants involved in cellular susceptibility to chemotherapeu-
tic agents without a priori assumptions about the genes. To date,
research has focused on known candidate genes involved in pharma-
cokinetic and pharmacodynamic pathways for specific chemotherapy.
METHODS: Three-generation CEPH pedigrees were used to
evaluate the genetic contribution to cellular growth inhibition by
exposing the cells to increasing concentrations of cisplatin for 48
hours or carboplatin for 72 hours.
RESULTS: The heritability of cisplatin- and carboplatin-induced
cytotoxicity was found to be between 0.38–0.47 (p0.0001) and
0.36–1.0 (p0.02), respectively. The most significant findings from
linkage analysis for cisplatin were on chromosome 1 at 44 cM in
variance components analysis and chromosome 12 at 147 cM in
nonparametric linkage analysis. Candidate genes within a 1-lod con-
fidence interval surrounding the peaks on chromosome 1 (188 genes)
and 12 (106 genes) included CASP9, SFN, STMN1, UBC, POLE and
ZNF84. Using expression array, we compared gene expression dif-
ferences at baseline and changes over time following treatment with
cisplatin. Genes common to linkage analysis and expression array
included ZNF84, RERE, NPPB, and SFRS8.
CONCLUSIONS: These data show the power of using large,
extensively genotyped pedigrees with microarray analysis for evalu-
ating the genetic contribution to sensitivity of cell growth inhibition
by anticancer agents.
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GRAPEFRUIT JUICE INGESTION REDUCES TALINOLOL
SERUM CONCENTRATION. U. I. Schwarz, MD, D. Seemann, R.
Oertel, PhD, S. Miehlke, MD, E. Kuhlisch, PhD, M. F. Fromm, MD,
R. B. Kim, MD, D. G. Bailey, PhD, W. Kirch, MD, Div. of Clin.
Pharmacol., Vanderbilt Univ., Inst. of Clin. Pharmacol., Tech. Univ.
Dresden, Med. Depart. I, Tech. Univ. Dresden Hospital, Inst. of Med.
Informatics/Biometrics, Tech. Univ. Dresden, Dr. M. Fischer-Bosch-
Inst. Stuttgart, Div. of Clin. Pharmacol., Vanderbilt Univ., Dep. of
Medicine, Univ. Western Ontario, Inst. of Clin. Pharmacol., Tech.
Univ. Dresden, Nashville, TN.
BACKGROUND/AIM: The objective was to evaluate the effect
of single and repeated grapefruit juice relative to water on oral
pharmacokinetics (PK) of the non-metabolized and P-glycoprotein
(Pgp)-transported drug talinolol in humans, and to assess the impact
of grapefruit juice on Pgp and intestinal uptake transporters.
METHODS: Oral PK of 50mg talinolol was determined with
water, single (300mL), and repeated grapefruit juice intake (6 days,
900mL/day) in 24 healthy Caucasians. MDR1 mRNA and Pgp levels
were measured in duodenal biopsies of 3 subjects before and after
juice. All subjects were genotyped for three MDR1 polymorphisms
(1236CT, 2677GT/A, 3435CT).
RESULTS: Single grapefruit juice decreased the talinolol AUC,
Cmax, and urinary excretion values to 56% (P.001), 57% (P.001)
and 58% (P.001), respectively, of those with water; repeated grape-
fruit juice showed a 50 to 65% reduction (P.01). Single or repeated
juice intake did not affect CLR, t1/2, and tmax. MDR1 mRNA and Pgp
levels in duodenal biopsies did not differ. MDR1 genotypes were not
associated with altered PK of talinolol.
CONCLUSION: Since both single and repeated juice intake
lowered, rather than increased talinolol AUC without changing Pgp
expression, our findings suggest constituents in grapefruit juice pref-
erentially inhibited intestinal uptake rather than Pgp.
OI-B-2
CYP2A6 GENOTYPE AND TOXICITY OF NICOTINE IN
NEVER SMOKERS. D. A. Dempsey, MD, P. Jacob III, PhD, R. F.
Tyndale, PhD, E. Hoffmann, MSc, N. L. Benowitz, MD, University
of California, San Francisco, University of Toronto, San Francisco,
CA.
BACKGROUND/AIMS: To examine genetic factors that influ-
ence sensitivity to nicotine (Nic) in never smokers.
METHODS: 20 Caucasian and 20 Asian never smokers received
7 mg nicotine skin patches, with frequent blood levels, subjective and
cardiovascular (CV) effect monitoring. CYP2A6, the enzyme primar-
ily responsible for Nic metabolism, was genotyped.
RESULTS: 25 subjects had wild type alleles (*1A and/or *1B) for
CYP2A6, while 15 subjects had CYP2A6 variant alleles (*4, *9, *10)
which are associated with slower Nic metabolism (Var-2A6). 8
subjects vomited, of whom 75% had Var-2A6 compared to 25% in
those who did not (p0.02). Nic levels (AUC 0–90min) were sig-
nificantly higher in those who vomited. Var-2A6 subjects had more
adverse responses to Nic including reduced alertness, concentration
and contentedness, and, more lightheadedness and nausea (all
p0.05). CV responses did not differ by genotype.
CONCLUSIONS: Variant CYP2A6 (*4, *9, *10) genotype is
associated with more toxicity from Nic in never smokers. Genotype
could influence responses to the first cigarette in never smokers and
responses to Nic medications used to treat Nic addiction. Supported
by USDPH-DA02277 and CIHR MOP53248.
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